These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 34278933)
21. Resistance Mechanisms to Targeted Therapies in McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358 [No Abstract] [Full Text] [Related]
22. Tumour heterogeneity and resistance to cancer therapies. Dagogo-Jack I; Shaw AT Nat Rev Clin Oncol; 2018 Feb; 15(2):81-94. PubMed ID: 29115304 [TBL] [Abstract][Full Text] [Related]
23. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. Govindan R; Mandrekar SJ; Gerber DE; Oxnard GR; Dahlberg SE; Chaft J; Malik S; Mooney M; Abrams JS; Jänne PA; Gandara DR; Ramalingam SS; Vokes EE Clin Cancer Res; 2015 Dec; 21(24):5439-44. PubMed ID: 26672084 [TBL] [Abstract][Full Text] [Related]
24. Lung Cancer Heterogeneity and New Strategies for Drug Therapy. Wang DC; Wang W; Zhu B; Wang X Annu Rev Pharmacol Toxicol; 2018 Jan; 58():531-546. PubMed ID: 28977762 [TBL] [Abstract][Full Text] [Related]
25. Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer. Kruglyak KM; Lin E; Ong FS Adv Exp Med Biol; 2016; 890():123-36. PubMed ID: 26703802 [TBL] [Abstract][Full Text] [Related]
26. Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy. Wu D; Wang DC; Cheng Y; Qian M; Zhang M; Shen Q; Wang X Semin Cancer Biol; 2017 Feb; 42():13-19. PubMed ID: 27840278 [TBL] [Abstract][Full Text] [Related]
27. Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors. Spagnuolo A; Maione P; Gridelli C Expert Opin Emerg Drugs; 2018 Sep; 23(3):231-241. PubMed ID: 30251885 [TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor receptor T790M testing in progressed lung cancer: A review of sensitive methods for analysis of tissue and liquid biopsy samples. Chougule A; Basak S Indian J Cancer; 2017 Dec; 54(Supplement):S45-S54. PubMed ID: 29292708 [TBL] [Abstract][Full Text] [Related]
30. Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer. Murtuza A; Bulbul A; Shen JP; Keshavarzian P; Woodward BD; Lopez-Diaz FJ; Lippman SM; Husain H Cancer Res; 2019 Feb; 79(4):689-698. PubMed ID: 30718357 [TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer. Galvani E; Alfieri R; Giovannetti E; Cavazzoni A; La Monica S; Galetti M; Fumarola C; Bonelli M; Mor M; Tiseo M; Peters GJ; Petronini PG; Ardizzoni A Curr Pharm Des; 2013; 19(5):818-32. PubMed ID: 22973953 [TBL] [Abstract][Full Text] [Related]